Abstract 3488: External validation of lysyl oxidase-like 2 (LOXL2) as a novel prognostic marker for gastro-entero-pancreatic neuroendocrine tumors (GEP-NET)
Jorge Barriuso(Queen's University Belfast), Marta Mendiola(Hospital Universitario La Paz), Clara García-Calderón(Hospital Universitario Virgen del Rocío), Rocio García‐Carbonero(Research Institute Hospital 12 de Octubre), Laura Guerra(Hospital Universitario La Paz), Cristina Álvarez‐Escolá(Hospital Universitario La Paz), Victoria Heredia-Soto(Hospital Universitario La Paz), Ana Custodio(Hospital Universitario La Paz), Ángela Lamarca(Hospital Universitario Fundación Jiménez Díaz), M. De Miguel(Hospital Universitario La Paz), Marta Benavent(Hospital Universitario Virgen del Rocío), Emilio Burgos(Hospital Universitario Infanta Sofía), Jaime Feliú(Hospital Universitario La Paz), Elsa Bernal, Jose Castell(Hospital Universitario La Paz)
Cited by 0
Related Papers
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
|The Lancet Oncology|2021|741
Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|502